Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 3/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.34 |
| ▸ | ALKBH1 | Q13686 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL666743 | 0.91 | NPC1 (0.40) | PTGER4PTGER3PTGER2PTGER1CCR2 | |
| SCHEMBL667685 | 0.90 | CCR2 (0.31) | CCR2CCR5 | |
| SCHEMBL661889 | 0.86 | ALKBH1 (0.37) | CCR2CCR5ALKBH1 | |
| SCHEMBL666226 | 0.84 | PPARD (0.35) | CCR2CCR5PPARGPPARDPPARA | |
| SCHEMBL667884 | 0.84 | TP53 (0.34) | CCR2CCR5PPARDPPARA | |
| SCHEMBL661383 | 0.83 | PPARG (0.43) | PPARGPPARA | |
| SCHEMBL661490 | 0.83 | MAPT (0.34) | CCR2CCR5ALKBH1 | |
| SCHEMBL667422 | 0.82 | PPARG (0.39) | PPARGPPARA | |
| SCHEMBL670411 | 0.79 | NPC1 (0.45) | CCR2CCR5 | |
| SCHEMBL667706 | 0.78 | CCR2 (0.34) | CCR2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046308-A1 | NOVEL ALPHA-PHENOXYBENZENEACETIC ACID DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME | KOWA COMPANY, LTD. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046308-A1 | NOVEL ALPHA-PHENOXYBENZENEACETIC ACID DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME | PPARA, PPARG, PPARD | PTGER4 558/4885PTGER3 302/4885PTGER2 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.